Drug intelligence / Profile preview

HLA-A siRNA

Development stage
Preclinical
Lead developer
University of Nebraska Medical Center
Modality
Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intravenous
01

Overview

HLA-A siRNA is a small interfering RNA (siRNA) designed to silence the expression of the Human Leukocyte Antigen A (HLA-A) heavy chain. HLA-A is a critical component of the HLA class I complex, which is primarily responsible for presenting endogenous antigens to CD8+ cytotoxic T cells. In oncological research, particularly concerning pancreatic ductal adenocarcinoma (PDAC), HLA-A siRNA is utilized to investigate the non-immunological roles of HLA class I molecules in tumor progression. Experimental evidence suggests that HLA-A expression can influence the proliferation and migration of pancreatic cancer cells, with its effects varying across different cell lines. By knocking down HLA-A, researchers aim to elucidate how these molecules contribute to the pathogenesis and potential immune escape mechanisms of pancreatic cancer.

Other names
HLA-A heavy chain siRNAsiRNA specific for HLA-A heavy chain
02

Targets

HLA-A (HLA class I histocompatibility antigen A alpha chain)

Beyond the preview

Go deeper on HLA-A siRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on HLA-A siRNA.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call